The 16,17-Double Bond Is Needed for Irreversible Inhibition of Human Cytochrome P45017α by Abiraterone (17-(3-Pyridyl)androsta-5,16-dien-3β-ol) and Related Steroidal Inhibitors
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Abiraterone (17-(3-pyridyl)androsta-5,16-dien-3beta-ol, 1) is a potent inhibitor (IC50 4 nM for hydroxylase) of human cytochrome P45017alpha. To assist in studies of the role of the 16,17-double bond in its mechanism of action, the novel 17alpha-(4-pyridyl)androst-5-en-3beta-ol (5) and 17beta-(3-pyridyl)-16,17alpha-epoxy-5alpha-androst-3beta-ol (6) were synthesized. 3beta-Acetoxyetienic acid was converted in three steps into 5 via photolysis of the thiohydroxamic ester 8. Oxidation of an appropriate 16,17-unsaturated precursor (21) with CrO3-pyridine afforded the acetate (23) of 6. Inhibition of the enzyme by 1, the similarly potent 5,6-reduced analogue 19 (IC50 5 nM), and the 4, 16-dien-3-one 26 (IC50 3 nM) and by the less potent (IC50 13 nM) 3,5, 16-triene 25 is slow to occur but is enhanced by preincubation of the inhibitor with the enzyme. Inhibition following preincubation with these compounds is not lessened by dialysis for 24 h, implying irreversible binding to the enzyme. In contrast under these conditions the still potent (IC50 27 nM) 17alpha-(4-pyridyl)androst-5-en-3beta-ol (5) showed partial reversal after 5 h of dialysis and complete reversal of inhibition after 24 h. This behavior was also shown by the less potent 16,17-reduced 3-pyridyl compounds 3 and 24. Further, in contrast to the compounds (1, 19, 25, 26) with the 16,17-double bond, the inhibition of the enzymic reaction was not enhanced by preincubation either with 5 or with the 17beta-pyridyl analogues 3, 4, and 24 which also lack this structural feature. The results show that the 16,17-double bond is necessary for irreversible binding of these pyridyl steroids to cytochrome P45017alpha. However oxidation to an epoxide is probably not involved since epoxide 6 was only a moderately potent inhibitor (IC50 260 nM).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abiraterone acetate, a prodrug of abiraterone, is a selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 c17 (CYP17), a critical enzyme in testosterone synthesis, thereby blocking androgen synthesis by the adrenal glands and testes and within the prostate tumor.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [14]
Citations
Cites
Radical chemistry associated with the thiocarbonyl group
Crich, D., & Quintero, L. (1989) · Chemical Reviews · doi:10.1021/cr00097a001 · Cited by 496
Recent Developments of Free-Radical Substitutions of Heteroaromatic Bases
Minisci, F., Vismara, E., & Fontana, F. (1989) · HETEROCYCLES · doi:10.3987/rev-88-sr1 · Cited by 452
Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a022 · Cited by 379
Self-citationPharmacology of novel steroidal inhibitors of cytochrome P45017 (17α-hydroxylase/C17–20 lyase)
Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90131-7 · Cited by 253
Self-citationWong, C. H., & Matos, J. R. (1985) · The Journal of Organic Chemistry · doi:10.1021/jo00211a046 · Cited by 69
Angelastro, M. R., Laughlin, M. E., Schatzman, G. L., Bey, P., & Blohm, T. R. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)90854-1 · Cited by 46
Rollin, P. (1986) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)84938-2 · Cited by 40
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors
Barrie, S. E., Haynes, B. P., Potter, G. A., Chan, F. C. Y., Goddard, P. M., Dowsett, M., & Jarman, M. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)00225-7 · Cited by 37
Self-citationKurihara, T., Sugizaki, M., Kime, I., Wada, M., & Mitsunobu, O. (1981) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.54.2107 · Cited by 35
Alcohol inversion of 17β-steroids
Dodge, J. A., & Lugar, C. W. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00559-c · Cited by 33
An expeditious route to the northern part of retigeranic acid A from (R)-(-)-Carvone
Llera, J. M., & Fraser‐Reid, B. (1989) · The Journal of Organic Chemistry · doi:10.1021/jo00284a029 · Cited by 32
Self-citationThe nine contiguous chiral centers in streptovaricin A via pyranosidic homologation
Mootoo, D. R., & Fraser‐Reid, B. (1989) · The Journal of Organic Chemistry · doi:10.1021/jo00284a030 · Cited by 30
A novel approach to cardenolides
Harnisch, W., Morera, E., & Ortar, G. (1985) · The Journal of Organic Chemistry · doi:10.1021/jo00211a045 · Cited by 29
Lewis, E. S., & Miller, E. B. (1953) · Journal of the American Chemical Society · doi:10.1021/ja01098a050 · Cited by 23
Time-dependent inactivation of steroid C17(20) lyase by 17β-cyclopropyl ether-substituted steroids
Angelastro, M. R., Marquart, A. L., Weintraub, P. M., Gates, C. A., Laughlin, M. E., Blohm, T. R., & Peet, N. P. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00566-c · Cited by 19
Miljkovic, D. A., Gaši, K. M. P., Kindjer, M., Stanković, S. M., & Argay, G. (1987) · Tetrahedron · doi:10.1016/s0040-4020(01)89997-x · Cited by 5
Research works printed but not linked: 9
- Rowlands M. G., 1996, J. Med. Chem., 38, 4197
- Chan F. C. Y., 1996, J. Med. Chem., 39, 3323
- Burke D. F. Ph.D., 1994, University of London
- Sato T., 1995, J. Org. Chem., 60, 2629
- Garreg P., 1982, J. Chem Soc., Perkin Trans. 1, 681, 683
- Barton D. H. R., 1986, Tetrahedron Lett., 27, 1330
- Catagnino E., 1986, Tetrahedron Lett., 27, 6338
- Bo T., 1996, Synthesis, 324, 326
- Pearson A. J., 1985, J. Chem. Soc., Perkin Trans. 1, 267, 273
Cited by
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
“Adverse event leading to death* 20 (4) 12 (2) Adverse event of grade 1–4 in ≥15% of patients in either group Fatigue 212 (39) 185 (34) Back pain 173 (32) 173 (32) Arthralgia 154 (28) 129 (24) Nausea 120 (22) 118 (22) Constipation 125 (23) 103 (19) Hot flush 121 (22) 98 (18) Diarrhea 117 (22) 96 (18) Bone pain 106 (20)…”
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
In silico methods and tools for drug discovery
Shaker, B., Ahmad, S., Lee, J., Jung, C., & Na, D. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104851 · Cited by 607
Minisci reactions: Versatile CH-functionalizations for medicinal chemists
Duncton, M. A. J. (2011) · MedChemComm · doi:10.1039/c1md00134e · Cited by 607
Metadata
- Authors
- Jarman, M., Barrie, S. E., & Llera, J. M.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Jarman, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1998-12-01
- Volume
- 41
- Issue
- 27
- Pages
- 5375-5381
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2110171529
- Cited by
- 151
- References
- 16
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 6 · 2019: 8 · 2018: 5 · 2017: 5 · 2016: 15 · 2015: 9 · 2014: 7 · 2013: 16 · 2012: 11
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- abiraterone, irreversible enzyme inhibition, structure-activity relationship, androgen production
- MeSH terms
- Androstanols, Androstenes, Androstenols, Enzyme Inhibitors, Humans, Kinetics, Male, Pyridines, Steroid 17-alpha-Hydroxylase, Structure-Activity Relationship, Testis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.